Unique ID issued by UMIN | UMIN000026137 |
---|---|
Receipt number | R000030035 |
Scientific Title | Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial |
Date of disclosure of the study information | 2017/02/14 |
Last modified on | 2019/10/23 23:41:40 |
Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial
Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral TKA: randomized controlled trial
Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral total knee arthroplasty: randomized controlled trial
Intravenous versus combined intravenous and intra-articular tranexamic acid for simultaneous bilateral TKA: randomized controlled trial
Japan |
Osteoarthritis of the knee
Rheumatoid arthritis
Orthopedics |
Others
NO
To evaluate whether combined intravenous and intra-articular administration of tranexamic acid reduced perioperative blood loss compared with intravenous-only administration of tranexamic acid for the patients undergoing simultaneous bilateral total knee arthroplasty.
Safety,Efficacy
The volume of perioperative blood loss measured using the calculated blood volume and change in hemoglobin from preoperative to postoperative day 3
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Active
NO
NO
NO
2
Treatment
Medicine |
The combined tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first knee. After closure of the capsule and retinaculum, 1000 mg of tranexamic acid (10 mL of 100 mg/mL tranexamic acid) was administered intra-articularly for each knee. Six hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously.
The intravenous tranexamic acid group received 1000 mg of tranexamic acid administered intravenously just before skin incision of the first knee. After closure of the capsule and retinaculum, 10 mL of normal saline was administered intra-articularly for each knee. Six hours after the first intravenous administration of tranexamic acid, 1000 mg of tranexamic acid was again given intravenously.
20 | years-old | <= |
Not applicable |
Male and Female
Patients undergoing simultaneous bilateral total knee arthroplasty
Known allergic reaction to tranexamic acid
Patients with preoperative hemoglobin level < 11.0 g/dL
Refusal of blood products
Enrollment in another interventional clinical trial within 6 months prior to surgery
32
1st name | |
Middle name | |
Last name | Sachiyuki Tsukada |
Hokusuikai Kinen Hospital
Orthopaedic Surgery
3-2-1 Higashihara, Mito, Ibaraki 310-0035, Japan
0293033003
s8058@nms.ac.jp
1st name | |
Middle name | |
Last name | Sachiyuki Tsukada |
Hokusuikai Kinen Hospital
Orthopaedic Surgery
3-2-1 Higashihara, Mito, Ibaraki 310-0035, Japan
0293033003
s8058@nms.ac.jp
Hokusuikai Kinen Hospital
Hokusuikai Kinen Hospital
Self funding
NO
2017 | Year | 02 | Month | 14 | Day |
Published
https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-019-2890-8
77
Completed
2017 | Year | 02 | Month | 14 | Day |
2017 | Year | 02 | Month | 15 | Day |
2017 | Year | 02 | Month | 14 | Day |
2019 | Year | 10 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030035